ArticleResearch and practice in thrombosis and haemostasis2019
Direct oral anticoagulants in extremely obese patients: OK to use?
Article in Research and practice in thrombosis and haemostasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.Clinical pharmacokinetics · 2022Pooled it
- Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.Journal of thrombosis and thrombolysis · 2024Observational
- Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.European journal of clinical pharmacology · 2023Observational
- Review
- Management of venous thromboembolism in morbidly obese patients: a 10-year review.Journal of thrombosis and thrombolysis · 2023Article
- Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment.Research and practice in thrombosis and haemostasis · 2022Article
- Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.Journal of clinical medicine · 2021Article
- Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.Journal of clinical medicine · 2021Article
- Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli.ERJ open research · 2021Article
- Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020Review
- Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis.Research and practice in thrombosis and haemostasis · 2020Article
- Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).Expert opinion on therapeutic patents · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.